公开(公告)号：US07128909B2

公开(公告)日：2006-10-31

申请号：US09147367

申请日：1997-06-09

Applicant: Ulf Schröder

Inventor： Ulf Schröder

IPC: A61K39/00 ,  A61K39/12 ,  A61K39/15 ,  A61K39/02

CPC classification number: C12N7/00 ,  A61K9/0019 ,  A61K9/1274 ,  A61K39/05 ,  A61K39/12 ,  A61K39/145 ,  A61K39/15 ,  A61K39/39 ,  A61K47/12 ,  A61K47/14 ,  A61K2039/5252 ,  A61K2039/543 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/55555 ,  C12N2720/12334 ,  C12N2760/16134 ,  C12N2760/16151 ,  Y10S514/937

Abstract: A pharmaceutical formulation for parenteral or mucosal administration of antigens and/or vaccines to humans and animals, comprising monoglyceride preparations having at least 80% monoglyceride content and where the acyl group contains from 6 to 24 carbon atoms, together with fatty acids where the number of carbon atoms may be varied between 4 and 22.

Abstract translation: 一种用于胃肠外或粘膜给予人和动物的抗原和/或疫苗的药物制剂，其包含具有至少80％单酸甘油酯含量的单酸甘油酯制剂，其中酰基含有6至24个碳原子，其中脂肪酸的数目 碳原子可以在4和22之间变化。

公开(公告)号：US20050281842A1

公开(公告)日：2005-12-22

申请号：US11194159

申请日：2005-08-01

Applicant: Kelly Knape ,  Stephanie Dykstra ,  Mary Tinant

Inventor： Kelly Knape ,  Stephanie Dykstra ,  Mary Tinant

IPC: A61K39/15 ,  A61K39/215 ,  A61K39/295

CPC classification number: A61K39/15 ,  A61K39/0258 ,  A61K39/08 ,  A61K39/12 ,  A61K39/215 ,  A61K2039/5252 ,  A61K2039/552 ,  A61K2039/70 ,  C12N2720/12334 ,  C12N2770/20034 ,  Y02A50/474

Abstract: Inactivated scours vaccines for immunization and protection of bovine animals from disease caused by infection with bovine rotavirus and bovine coronavirus, which comprise and effective amount of at least one inactivated viral strain are described. Polyvalent inactivated vaccines further comprising an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed. Said vaccines are prepared from one or more strains of rota- and coronavirus, C. perfringens Type C bacteria and E. coli bacteria, and combinations thereof. Preferably, a polyvalent inactivated vaccine is provided for parenteral administration. Passive immunity is achieved in neonatal calves via immunization of pregnant cows prior to birth.

Abstract translation: 描述了用于免疫和保护牛动物免受由牛轮状病毒和牛冠状病毒感染引起的疾病的灭活的冲洗疫苗，其包含和有效量的至少一种灭活的病毒株。 还公开了进一步包含有效量的抗一种或多种另外的病原生物或病毒的抗原成分的多价灭活疫苗。 所述疫苗由一种或多种旋转和冠状病毒，产气荚膜梭菌C型细菌和大肠杆菌细菌及其组合制备。 优选地，为肠胃外给药提供多价灭活的疫苗。 通过在出生前对怀孕的母牛进行免疫，在新生儿小牛中实现被动免疫。

公开(公告)号：US20050130127A1

公开(公告)日：2005-06-16

申请号：US10714534

申请日：2003-11-14

Applicant: Petrus Rottier ,  Cornelis De Haan ,  Bert Haijema ,  Berend-Jan Bosch

Inventor： Petrus Rottier ,  Cornelis De Haan ,  Bert Haijema ,  Berend-Jan Bosch

IPC: C12N15/09 ,  A61K35/76 ,  A61K38/00 ,  A61K39/00 ,  A61K39/215 ,  A61K39/225 ,  A61K39/395 ,  A61K48/00 ,  A61K49/00 ,  A61P1/16 ,  A61P7/00 ,  A61P7/04 ,  A61P7/06 ,  A61P11/00 ,  A61P31/00 ,  A61P31/12 ,  A61P31/16 ,  A61P31/20 ,  A61P31/22 ,  A61P35/02 ,  A61P37/04 ,  C07K14/165 ,  C12N5/06 ,  C12N5/16 ,  C12N7/00 ,  C12N7/04 ,  C12N15/86 ,  C12P21/06 ,  C12Q1/68 ,  C12Q1/70 ,  G01N33/569

CPC classification number: A61K39/215 ,  A61K38/00 ,  A61K39/12 ,  A61K39/225 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/552 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10034 ,  C12N2710/16334 ,  C12N2710/16734 ,  C12N2720/10034 ,  C12N2720/12234 ,  C12N2720/12334 ,  C12N2740/13034 ,  C12N2740/15034 ,  C12N2750/10034 ,  C12N2750/14334 ,  C12N2760/16134 ,  C12N2760/18134 ,  C12N2760/18434 ,  C12N2760/18534 ,  C12N2770/10034 ,  C12N2770/16034 ,  C12N2770/20021 ,  C12N2770/20022 ,  C12N2770/20023 ,  C12N2770/20034 ,  C12N2770/20043 ,  C12N2770/24334 ,  C12N2770/32134 ,  C12N2800/204 ,  G01N33/56983 ,  G01N2333/165

Abstract: The invention relates to the field of coronaviruses and diagnosis, therapeutic use, and vaccines derived therefrom. The invention provides replicative coronaviruses and virus-like particles (VLPs) from which large parts of their genome are (at least functionally) deleted without abolishing their replicative capacities. The deletion preferably results in at least a functional deletion in that the corresponding gene is not or is only partly expressed wherein the resulting gene product is dysfunctional or at least functionally distinct from a corresponding wild-type gene product. One result seen with VLPs provided with deletions as provided herein is that the deleted VLP, albeit capable of replication in vitro and in vivo, are generally well attenuated, in that they do not cause disease in the target host, making them very suitable for therapeutic use, such as a delivery vehicle for genes and other cargo (wherein specific targeting may be provided as well when desired), and for use as a vaccine, being attenuated while carrying important immunogenic determinants that help elicit an immune response.

Abstract translation: 本发明涉及冠状病毒和诊断领域，治疗用途以及从其衍生的疫苗。 本发明提供复制性冠状病毒和病毒样颗粒（VLP），其基因组的大部分（至少在功能上）被删除，而不消除其复制能力。 缺失优选至少导致功能缺失，因为相应的基因不是或仅部分表达，其中所得基因产物在相应的野生型基因产物中功能失调或至少在功能上不同。 在本文提供的具有缺失的VLP所见的一个结果是缺失的VLP虽然在体外和体内都能复制，但通常是很好的减毒，因为它们不会在靶宿主中引起疾病​​，使得它们非常适合于治疗 使用，例如用于基因和其他货物的递送载体（其中当需要时可以提供特异性靶向），并用作疫苗，同时携带有助于引发免疫应答的重要的免疫原性决定簇。

公开(公告)号：US20040223981A1

公开(公告)日：2004-11-11

申请号：US10181908

申请日：2003-08-08

Inventor： Albert Z. Kapikian ,  Robert M. Chanock ,  Timo Vesikari

IPC: A61K039/15

CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/545 ,  A61K2039/55 ,  C12N2720/12334

Abstract: The present invention provides compositions for making a medicament and methods for the administration of a vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Humannullrhesus reassortant rotavirus compositions were made which when were administered during the first 7 to about 10 days of life, provided a composition which was non-reactogenic followed by booster immunizations at 16 to 18 weeks or 14 to 20 weeks, up to 1 year of age. The immune response induced by the initial neonatal administration of the live rotavirus vaccine composition protects the infant from the reactogenicity of the composition when administered as a second dose at or after 2 months of age. Administration of thee immunogenic composition also is expected to ablate or significantly diminish the increase in the excess of imussusception observed 3 to 7 days following administration of the initial dose of rotavirus vaccine at about 2 to 4 months.

Abstract translation: 本发明提供了用于制备药物的组合物和用于施用用于防止人类轮状病毒病而没有显着的反应原性的疫苗组合物的方法。 制造人类重配轮状病毒组合物，其在生命的头7至10天内施用时，提供了在16至18周或14至20周，至多1岁的组合物，其是非反应原性的，然后进行加强免疫 。 由活轮状病毒疫苗组合物的初始新生儿施用引起的免疫应答在2个月龄或之后以第二剂量施用时保护婴儿免受组合物的反应原性。 在约2至4个月时，在施用初始剂量的轮状病毒疫苗后3至7天观察到，免疫原性组合物的施用也预期消融或显着降低观察到的过度的惊跳症的增加。

公开(公告)号：US20040009937A1

公开(公告)日：2004-01-15

申请号：US10353137

申请日：2003-01-27

Inventor： Wei Chen ,  Xiaoli Fu ,  Sherry Nouraini ,  Zhiqing Zhang

IPC: A61K048/00 ,  A61L009/04 ,  A61K009/14

CPC classification number: A61K48/0091 ,  A61K35/744 ,  A61K36/06 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/2026 ,  A61K38/2066 ,  A61K38/208 ,  A61K38/21 ,  A61K38/27 ,  A61K38/28 ,  A61K38/29 ,  A61K39/00 ,  A61K39/02 ,  A61K39/12 ,  A61K39/145 ,  A61K39/15 ,  A61K39/292 ,  A61K48/0008 ,  A61K2039/5156 ,  A61K2039/523 ,  A61K2039/541 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/55522 ,  A61K2039/55533 ,  A61K2039/55566 ,  A61K2039/57 ,  C12N2720/12334 ,  C12N2730/10134 ,  C12N2760/16134 ,  Y02A50/386 ,  Y02A50/397 ,  Y02A50/401 ,  Y02A50/403 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/466

Abstract: Methods and compostions related to the fields of bacteriology, immunology and gene therapy are provided. In general modified microflora for the delivery of vaccines, allergens and therapeutics to the mucosal surfaces of the respiratory tract are provided. In particular, the compositions and methods are directed at inducing an M-cell mediated immune response to pathogenic diseases. Specifically, methods of vaccine preparation, delivery and mucosal immunization using a Lactic Acid Bacteria (LAB), yeast and LAB that have been modified through fusion with E. coli to either present on its cell surface, or secrete, antigenic epitopes derived from pathogenic microorganisms and/or to secrete a therapeutic protein sequence are disclosed.

Abstract translation: 提供了与细菌学，免疫学和基因治疗领域相关的方法和组合。 提供了一般用于将疫苗，变应原和治疗剂递送至呼吸道粘膜表面的改良的微生物群落。 特别地，组合物和方法旨在诱导M细胞介导的致病性疾病的免疫应答。 具体地，使用已经通过与大肠杆菌融合修饰以存在于其细胞表面上的乳酸菌（LAB），酵母和LAB，或分泌来自病原微生物的抗原表位的疫苗制备，递送和粘膜免疫的方法 和/或分泌治疗性蛋白质序列。

公开(公告)号：US06656719B1

公开(公告)日：2003-12-02

申请号：US09176492

申请日：1998-10-21

Applicant: Sandra L. Gould ,  David K. Robinson ,  Daniel J. Distefano ,  T. Craig Seamans

Inventor： Sandra L. Gould ,  David K. Robinson ,  Daniel J. Distefano ,  T. Craig Seamans

IPC: C12N700

CPC classification number: A61K39/15 ,  A61K39/12 ,  C12N5/0043 ,  C12N7/00 ,  C12N2500/25 ,  C12N2500/40 ,  C12N2501/02 ,  C12N2501/11 ,  C12N2501/39 ,  C12N2501/395 ,  C12N2720/12334 ,  C12N2720/12351

Abstract: Defined serum-free, low protein media (LPKM), that supports 1) Vero cell growth for up to 20 passages, 2) Vero cell growth on microcarriers and 3) rotavirus production is provided. Maximum cell densities attained are 60-100% of that in serum-containing medium; the doubling time is equal to that for cells in serum containing medium. Rotavirus titers achieved in LPKM-1 are 50-100% of the serum-containing process. Finally, since LPKM-1 contains no animal-sourced proteins, the problems associated with the serum-containing rotavirus production process (i.e. lengthy wash steps before infection, potential introduction of adventitious agents and lot-to-lot variability) can be avoided; while maintaining nearly equivalent product titers.

Abstract translation: 定义无血清，低蛋白质培养基（LPKM），其支持1）Vero细胞生长多达20代，2）提供微载体上的Vero细胞生长和3）轮状病毒生产。 获得的最大细胞密度为含血清培养基的最大细胞密度的60-100％; 倍增时间与含血清培养基中的细胞相同。 在LPKM-1中实现的轮状病毒滴度为含血清过程的50-100％。 最后，由于LPKM-1不含动物来源的蛋白质，因此可以避免与血清轮状病毒生产过程相关的问题（即感染前长时间的洗涤步骤，潜在的引入外来物质和批次间变异性）。 同时保持几乎相当的产品滴度。

公开(公告)号：US20030190314A1

公开(公告)日：2003-10-09

申请号：US10375844

申请日：2003-02-25

Applicant: The Lauridsen Group

Inventor： Joy M. Campbell ,  Ronald E. Strohbehn ,  Eric M. Weaver ,  Barton S. Borg ,  Louis E. Russell ,  Francisco Javier Polo Pozo ,  John D. Arthington ,  James D. Quigley III

IPC: A61K039/395 ,  A61K035/16

CPC classification number: A61K39/15 ,  A23K10/00 ,  A61K35/16 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/505 ,  A61K2039/542 ,  A61K2039/552 ,  C07K16/02 ,  C07K16/04 ,  C07K16/06 ,  C07K16/065 ,  C12N2720/12334 ,  C12N2770/10011 ,  C12N2770/10034

Abstract: Methods and compositions are disclosed for the dietary modulation of the immune system and gut microbial response in animals. Applicant has identified that oral administration of a supplemental spray dried plasma purified from animal serum can modulate serum IgG levels for treatment in such things as diminished immune capacity, intestinal microbial balance, autoimmune disorders, potentiation of vaccination protocols, and improvement of overall health and weight gain in animals, including humans.

Abstract translation: 公开了用于免疫系统的饮食调节和动物肠内微生物反应的方法和组合物。 申请人已经确定，从动物血清中纯化的补充喷雾干燥血浆的口服给药可以调节血清IgG水平以进行治疗，例如免疫能力降低，肠微生物平衡，自身免疫疾病，增强疫苗接种方案以及提高整体健康和体重 在动物，包括人类的增益。

公开(公告)号：US20030180372A1

公开(公告)日：2003-09-25

申请号：US10100165

申请日：2002-03-19

Inventor： Shobhana Dattatraya Kelkar ,  Rejendra Prabhakar Deolankar

IPC: A61K039/15 ,  A61K035/20 ,  C12N007/00 ,  C12N007/01

CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/54 ,  A61K2039/55 ,  A61K2039/55566 ,  C07K16/10 ,  C12N2720/12334

Abstract: The present invention relates to a colostrum and to a process for the preparation thereof to prevent rotavirus induced diarrhoea of G1 to G4, G5 and G6, G8 to G10. The process comprises in mixing the rotavirus specimens from infected children with an adjuvant to obtain water in oil emulsions. The virus singularly or the emulsion is inoculated into pregnant goats. The colostrum is collected from the immunized goats after delivery, dried and added to a carrier.

Abstract translation: 本发明涉及初乳及其制备方法，以预防轮状病毒诱导的G1至G4，G5和G6，G8至G10的腹泻。 该方法包括将来自感染儿童的轮状病毒样品与佐剂混合以获得油包水乳剂。 将病毒单独或将乳液接种到怀孕的山羊中。 在分娩后从免疫的山羊收集初乳，干燥并加入载体中。

公开(公告)号：US20030103989A1

公开(公告)日：2003-06-05

申请号：US10067792

申请日：2002-02-08

Applicant: AGRESEARCH LIMITED

Inventor： Alison Joy Hodgkinson ,  Steven Charles Hodgkinson

IPC: A61K039/00

CPC classification number: A61K39/15 ,  A61K35/20 ,  A61K39/0258 ,  A61K39/12 ,  A61K39/215 ,  A61K2039/5252 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/552 ,  A61K2039/55566 ,  A61K2039/70 ,  C07K16/04 ,  C12N2720/12334 ,  C12N2770/20034 ,  Y02A50/474

Abstract: The present invention provides a process for producing immunoglobulin A in the milk of hyperimmunised ruminants using a 3 route immunisation protocol and uses for the resultant product. These products are useful in producing formulations useful for passive immunisation against selected pathogens, especially in preparations for food products and dietary preparations.

Abstract translation: 本发明提供使用3途径免疫方案在超免疫反刍动物乳中产生免疫球蛋白A的方法，并用于所得产物。 这些产品可用于制备适用于针对选定病原体的被动免疫的制剂，特别是用于食品和膳食制剂的制剂。

公开(公告)号：US20030099633A1

公开(公告)日：2003-05-29

申请号：US09973284

申请日：2001-10-09

Inventor： Joy M. Campbell ,  Ronald E. Strohbehn ,  Eric M. Weaver ,  Barton S. Borg ,  Louis E. Russell ,  Francisco Javier Polo Pozo ,  John D. Arthington ,  James D. Quigley

IPC: A61K039/395 ,  A01H001/00 ,  C12P021/02 ,  C12N001/21

CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/505 ,  A61K2039/542 ,  A61K2039/552 ,  A61K2039/55516 ,  A61K2039/70 ,  C07K16/02 ,  C07K16/04 ,  C07K16/06 ,  C07K16/065 ,  C12N2720/12334 ,  C12N2770/10034

Abstract: Methods and compositions are disclosed for modulating the immune system of animals. Applicant has identified that oral administration of immunoglobulins purified from animal serum can modulate serum IgG levels for treatment of autoimmune disorders, potentiation of vaccination protocols, and improvement of overall health and weight gain in animals, including humans.

Abstract translation: 公开了调节动物免疫系统的方法和组合物。 申请人已经确定，从动物血清中纯化的免疫球蛋白的口服给药可以调节血清IgG水平以治疗自身免疫性疾病，增强疫苗接种方案，以及改善包括人在内的动物的整体健康和体重增加。